You are here: Industry Insights > AstraZeneca

News List

Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease worldpharmanews
June 24, 2019
Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease.
AstraZeneca’s drug showed reduced Chronic Kidney Disease progress in cases of type-2 diabetes expresspharma
June 21, 2019
AstraZeneca has announced that a pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial, the broadest cardiovascular outcomes trial of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has shown that Forxiga (dapaglif
AstraZeneca’s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment expresspharma
June 21, 2019
British drugmaker AstraZeneca announced that its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel’s consent in April.
AZ' Calquence shows PFS benefit in CLL patients pharmatimes
June 18, 2019
AstraZeneca has presented detailed data showing that Calquence (acalabrutinib) significantly prolonged progression free survival (PFS) in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL).
Positive results for AZ’ Lokelma in hyperkalaemia pharmatimes
June 18, 2019
AstraZeneca has announced a statistically significant and clinically meaningful improvement from its Phase IIIb DIALIZE trial, investigating the efficacy and safety of Lokelma (sodium zirconium cyclosilicate) for the treatment of hyperkalaemia in patients
Lonza to Expand HPAPI Development and Manufacturing Capacity contractpharma
June 18, 2019
Will develop new facilities at Visp site; enters long term mfg. agreement with AstraZeneca.
AZ’ Calquence hits endpoints in late-stage leukemia trial pharmatimes
June 11, 2019
AstraZeneca has announced more positive results, this time from its Phase III ELEVATE-TN trial of Calquence (acalabrutinib) in patients with previously-untreated chronic lymphocytic leukaemia (CLL).
AZ’ new headquarters double in price pharmatimes
June 11, 2019
The Times has reported that AstraZeneca’s new global headquarters in Cambridge has “more than doubled to £750 million, making it one of the most expensive corporate buildings in Britain.”
Starpharma Signs Second Oncology Agreement with AstraZeneca americanpharmaceuticalreview
June 06, 2019
Starpharma announced a Development and Option Agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product (DEP®) version of an undisclosed AstraZeneca major marketed oncology medicine.
‘Unprecedented’ results in AZ’ late-stage Lynparza trial pharmatimes
June 05, 2019
New data from a Phase III trial of AstraZeneca and MSD’s Lynparza (olaparib) has shown that 22% of patients receiving the monotherapy remained free of disease progression after two years vs. 10% on placebo, making the drug the first PARP inhibitor to demo

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page